一个没有抗生素的平台,可以消除持续的Helicobacter pylori感染,而不会破坏肠道微生物群
Yongkang Lai1,2, Tinglin Zhang3,4, Xiaojing Yin1
1Department of Gastroenterology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Acta pharmaceutica Sinica. B
|July 19, 2024
概括
一个新的无抗生素纳米粒子平台通过向生物膜和细胞内细菌,有效地根除了Helicobacter pylori. 这种方法为治疗失败提供了一个有希望的解决方案,并保护肠道健康.
科学领域:
- 生物材料科学 生物材料科学
- 传染性疾病 传染性疾病
- 药物运输 药物运输 药物运输
背景情况:
- 杆菌感染是胃癌的主要原因,抗生素耐药性导致广泛的治疗失败.
- 目前的抗生素治疗对细菌生物膜和细胞内病原体无效,并且可以破坏肠道微生物群.
研究的目的:
- 开发和评估一种无抗生素治疗平台,用于根除H. pylori.
- 解决传统抗生素治疗的局限性,包括耐药性和微生物群损伤.
主要方法:
- 一个无抗生素的多功能铜有机框架 (HKUST-1) 平台被开发出来,被包裹在脂质层 (酸,脂,胆固醇) 中,并涂上基托.
- 该平台被装入一个阿斯科尔比尔棕酸盐水凝 (AP@CS@Lip@HKUST-1) 中,用于针对性地向炎症部位输送.
- 该机制涉及静电吸引,矩阵金属蛋白酶的水解,细菌尿素酶和膜的破坏,生物膜的分散和自的促进.
主要成果:
- 在AP@CS@Lip@HKUST-1平台上演示了针对性的输送和破坏H. pylori.
- 它有效分散了生物膜,并促进了细胞内细菌的清除.
- 该平台缓解了炎症,并通过受控的Cu2+释放促进了粘膜修复,同时保留了肠道微生物群.
结论:
- 开发的AP@CS@Lip@HKUST-1平台提出了一种新的多功能策略,用于根除H. pylori感染.
- 这种无抗生素的方法克服了当前疗法的关键局限性,包括耐药性和微生物群破坏.
- 该平台显示出作为一种先进的治疗方法来治疗持久性H. pylori感染的显著潜力.
关键词:
这是一种抗炎症药物.没有抗生素的无抗生素.自自是一种自的过程.生物膜是一种生物膜.药物耐药性 药物耐药性 药物耐药性胃粘膜修复 胃粘膜修复感染了Helicobacter pylori的病毒.我们的肠道微生物群.更多相关视频
10:44One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
Published on: June 18, 2016
9.7K
04:56Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
Published on: May 16, 2025
196
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
345
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
345
01:26Peptic Ulcer Disease IV: Management
83
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
83
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
364
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
364
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
105
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
105
01:30Peptic Ulcer Disease I: Introduction
162
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
162
01:23Gastritis III: Clinical Manifestations and Management
204
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
204